 |
talimogene laherparepvec |
|---|---|
| Trade Name | Imlygic |
| Orphan Indication | Metastatic Melanoma |
| USA Market Approval | USA |
| USA Designation Date | 2011-03-14 00:00:00 |
| Sponsor | BioVex, Inc. (subsidiary of Amgen);Amgen, Mail Stop 17-2-B;Thousand Oaks, California, 91320 |
| |
talimogene laherparepvec |
|---|---|
| Trade Name | Imlygic |
| Orphan Indication | Metastatic Melanoma |
| USA Market Approval | USA |
| USA Designation Date | 2011-03-14 00:00:00 |
| Sponsor | BioVex, Inc. (subsidiary of Amgen);Amgen, Mail Stop 17-2-B;Thousand Oaks, California, 91320 |